Company Profile
Context Therapeutics Stock Price, News & Catalysts
- Ticker:
- CNTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.38 USD (+1.16%)
Close
Last updated: September 17, 2026
222M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, CNTX closed up 1.16% at $0.3834. No new same-company headline was identified in the current news window.
Company overview
Solid-Tumor T-Cell Engagers
Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors.
CTIM-76
CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen.
CT-95
CT-95 is a mesothelin-directed CD3 bispecific antibody in Phase 1 development for mesothelin-expressing solid tumors.
CT-202
CT-202 targets Nectin-4 and CD3 and is preparing to enter first-in-human testing, adding a third tumor-associated antigen to the platform.
Future catalysts
- Phase 1a interim data for CTIM-76 in June 2026.
- Phase 1 initiation for CT-202 in the third quarter of 2026.
- Phase 1a interim data for CT-95 in September 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Context Therapeutics (CNTX)?
Context Therapeutics (CNTX) most recently closed at 0.38 USD, a +1.16% move versus the previous session.
What is the market cap of Context Therapeutics (CNTX)?
Context Therapeutics currently has a market capitalization of 222M USD on BioPharmSignal.
What does Context Therapeutics do?
Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a mesothelin-directed CD3 bispecific...
On which exchange is CNTX stock listed?
Context Therapeutics (CNTX) is associated with NASDAQ, United States, Biopharma.
What is CTIM-76?
Phase 1a interim data for CTIM-76 in June 2026.
Which conditions is Context Therapeutics targeting with CTIM-76?
Phase 1a interim data for CTIM-76 in June 2026.
How does Context Therapeutics describe recent progress with CTIM-76?
Phase 1a interim data for CTIM-76 in June 2026.
What is CT-95?
CT-95 CT-95 is a mesothelin-directed CD3 bispecific antibody in Phase 1 development for mesothelin-expressing solid tumors.